ArticleOncology letters2024
A meta‑analysis assessing the cytotoxicity of nanoparticles on MCF7 breast cancer cells.
Article in Oncology letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Antitumor Activity of All-Trans Retinoic Acid and Curcumin-Loaded BSA Nanoparticles Against U87 Glioblastoma Cells.Life (Basel, Switzerland) · 2026Article
- Recent Advances in Machine Learning Models for Predicting Toxicity of Inorganic Nanoparticles.Chem & bio engineering · 2025Review
- Integrating machine-learning and nanotechnology to quantify pH-modulated oxaliplatin release.Scientific reports · 2025Article
- Green Synthesis of Gold Nanoparticles and Their Cytotoxic Effect in Breast Cancer: An Experimental and Theoretical Study.ACS applied bio materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study summarizes the current available literature regarding the viability of MCF7 breast cancer cells treated with gold (Au), silver (Ag) or zinc oxide (ZnO) nanoparticles at varying doses for 48 h. The data for this study were obtained from diverse research articles published between 2013 and 2023 using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. The evaluation focused on 20 PRISMA-compliant articles concerning MCF7 cells, yielding 137 outcome measures for meta-analysis. A generalized linear mixed model meta-analysis approach was employed to glean insights into the effects of novel nanoparticles on MCF7 breast cancer cells. The analysis covered a wide range of concentrations: Ag nanoparticles from 1.25 to 1,000 µg/ml, Au nanoparticles from 50 to 150 µg/ml, and ZnO nanoparticles from 1 to 1,000 µg/ml. Both intra-nanoparticle and inter-nanoparticle comparisons were conducted to detect differences. The findings showed that when concentrations reached or exceeded 60 µg/ml, considerable variation of cell viability was observed: Treatment with Ag nanoparticles resulted in cell viability ranging from 9 to 45%, ZnO nanoparticles resulted in cell viability ranging from 20 to 40%, and Au nanoparticles resulted in cell viability ranging from 3 to 58%. These findings indicated the significance of thoroughly exploring nanoparticle dosage to acquire a comprehensive understanding of their influence on cell viability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.